GLP-1 Showdown Set For Fall: Bydureon Gets New October Review Deadline
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk also announces it will start the 9,000-patient cardiovascular outcomes trial for competitor Victoza in the fall.